Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2022/03/040774
CTRI/2022/03/040774CompletedPhase 2

preclinical and clinical evaluation of the effect on oral administration of POONAI MEESAI CHOORANAM KUDINEER in the management of OOTHU SOBAI

Dr P Narmatha1 site in 1 country40 target enrollmentStarted: March 3, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
40
Locations
1
Primary Endpoint
REDUCTION IN SYMPTOMS
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

It is single arm trails for preclinical and clinical evaluation of the effects on oral administration of poonai meesai  chooranam kudineer in the management of oothu sobai

Study Design

Study Type
Interventional
Allocation
Not Applicable
Masking
Not Applicable

Eligibility Criteria

Ages
3.00 Year(s) to 12.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • •Oedema due to renal impairment.

Exclusion Criteria

  • •Children above 12 years Children below 3 years Hypothyroidism Cushing syndrome Oedema due to drug allergy Oedema mimics obesity in children Acute glomerular nephritis Chronic glomerular nephritis.

Outcomes

Primary Outcomes

REDUCTION IN SYMPTOMS

Time Frame: 21 days

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Dr P Narmatha
Sponsor Class
Other [self]

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 2
Preclinical and clinical evaluation of the effect of Siddha classical drug PARUMA NOI NIVARANA MAATHIRAI & NEERMULLI OORAL KUDINEER (oral administration ) along with PODI THIMIRTHAL ( external therapy) in the management of CHILDHOOD OBESITY.
CTRI/2022/02/040297Dr J Mangalavalli40
Completed
Phase 1
A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941Liver Disease
NCT01187186Astellas Pharma Inc16
Completed
Phase 1
A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy VolunteersHealthy
NCT01002963Pfizer56
Terminated
Phase 1
RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy SubjectsHealthy VolunteersImpaired Renal Function
NCT04252430MedDay Pharmaceuticals SA24
Terminated
Phase 1
HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy SubjectsHealthy VolunteersHepatic Impairment of Moderate Child Pugh Category
NCT04252417MedDay Pharmaceuticals SA15